Your browser is no longer supported. Please, upgrade your browser.
Settings
CTIC CTI BioPharma Corp. daily Stock Chart
CTIC [NASD]
CTI BioPharma Corp.
Index- P/E- EPS (ttm)-0.70 Insider Own0.39% Shs Outstand73.69M Perf Week8.65%
Market Cap84.86M Forward P/E- EPS next Y-0.70 Insider Trans0.00% Shs Float73.53M Perf Month-5.04%
Income-44.40M PEG- EPS next Q-0.15 Inst Own50.00% Short Float0.37% Perf Quarter-14.39%
Sales2.30M P/S36.90 EPS this Y-31.70% Inst Trans-5.34% Short Ratio0.39 Perf Half Y42.77%
Book/sh0.77 P/B1.47 EPS next Y0.00% ROA-66.00% Target Price- Perf Year27.61%
Cash/sh0.93 P/C1.21 EPS next 5Y- ROE-126.30% 52W Range0.62 - 1.95 Perf YTD-28.48%
Dividend- P/FCF- EPS past 5Y36.10% ROI-123.40% 52W High-42.05% Beta1.43
Dividend %- Quick Ratio5.20 Sales past 5Y-43.90% Gross Margin- 52W Low82.26% ATR0.07
Employees25 Current Ratio5.20 Sales Q/Q- Oper. Margin- RSI (14)44.47 Volatility8.66% 6.14%
OptionableYes Debt/Eq0.12 EPS Q/Q-0.40% Profit Margin- Rel Volume0.42 Prev Close1.20
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume712.15K Price1.13
Recom2.00 SMA202.70% SMA50-12.38% SMA200-3.73% Volume296,264 Change-5.83%
Jun-24-20Resumed JMP Securities Mkt Outperform $3
Mar-05-19Initiated Lake Street Buy $4
Mar-26-18Initiated Needham Buy $10
Mar-07-18Initiated JMP Securities Mkt Outperform $8
Sep-12-17Initiated Jefferies Buy $7.50
Feb-10-16Downgrade WallachBeth Hold → Sell
Feb-10-16Downgrade Piper Jaffray Overweight → Neutral
Feb-10-16Downgrade Ladenburg Thalmann Buy → Neutral
Nov-09-15Downgrade WallachBeth Buy → Hold $4.50 → $1.60
Aug-05-14Upgrade WallachBeth Hold → Buy $4.50
Mar-19-14Initiated WallachBeth Hold $4.50
Nov-04-13Initiated HC Wainwright Buy $4
Aug-06-20 04:05PM  
Jul-17-20 09:54AM  
Jul-06-20 07:47PM  
Jun-22-20 03:27PM  
Jun-01-20 04:22PM  
04:00PM  
02:22PM  
07:00AM  
May-28-20 07:00AM  
May-18-20 06:25AM  
Apr-27-20 07:00AM  
Apr-08-20 07:00AM  
Mar-27-20 07:00AM  
Mar-12-20 04:05PM  
Mar-06-20 06:48PM  
Feb-21-20 04:22PM  
Feb-14-20 07:00AM  
Feb-03-20 07:01AM  
Jan-27-20 07:14AM  
Dec-16-19 05:58AM  
Dec-09-19 10:30AM  
Dec-07-19 08:35AM  
Nov-06-19 09:08AM  
Nov-04-19 04:05PM  
Oct-01-19 07:00AM  
Aug-01-19 04:05PM  
Jul-18-19 07:00AM  
Jun-13-19 07:00AM  
May-29-19 07:00AM  
May-02-19 06:40PM  
04:05PM  
Apr-03-19 07:00AM  
Mar-13-19 05:33PM  
04:05PM  
Mar-12-19 07:00AM  
Feb-25-19 05:52PM  
Feb-20-19 07:00AM  
Feb-13-19 12:22AM  
Feb-11-19 07:00AM  
Feb-08-19 06:25PM  
Feb-01-19 07:01AM  
Dec-28-18 07:00AM  
Dec-18-18 04:01PM  
Dec-17-18 07:53PM  
Dec-14-18 07:47AM  
Dec-13-18 02:20PM  
10:03AM  
Nov-26-18 04:01PM  
Nov-23-18 07:35AM  
Nov-01-18 12:10PM  
09:40AM  
08:01AM  
Oct-25-18 07:01AM  
Oct-01-18 10:05AM  
07:01AM  
Sep-26-18 07:01AM  
Sep-07-18 01:20PM  
Sep-06-18 05:50PM  
Aug-29-18 01:47PM  
Aug-02-18 02:30PM  
09:40AM  
08:36AM  
08:00AM  
Jul-26-18 04:01PM  
Jul-19-18 11:14AM  
09:14AM  
08:00AM  
Jul-18-18 11:47AM  
07:00AM  
Jul-13-18 08:50AM  
Jul-10-18 09:33AM  
Jul-09-18 05:02PM  
04:36PM  
12:26PM  
07:58AM  
07:27AM  
07:06AM  
07:00AM  
Jul-02-18 07:00AM  
Jun-30-18 05:32PM  
Jun-14-18 07:02AM  
Jun-12-18 10:20AM  
Jun-06-18 07:01AM  
May-03-18 05:36PM  
04:01PM  
May-02-18 04:42PM  
Apr-26-18 04:05PM  
Apr-25-18 04:02PM  
Apr-18-18 03:57PM  
Mar-13-18 07:40AM  
Mar-09-18 07:05AM  
07:00AM  
Mar-07-18 04:27PM  
04:01PM  
01:15PM  
12:30PM  
Feb-28-18 11:07AM  
08:00AM  
Feb-14-18 04:05PM  
Feb-13-18 07:00AM  
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.